Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status.

Pigment cell & melanoma research - 1 Apr 2011

Zipser Marie C, Eichhoff Ossia M, Widmer Daniel S, Schlegel Natalie C, Schoenewolf Nicola L, Stuart Darrin, Liu Weihua, Gardner Humphrey, Smith Paul D, Nuciforo Paolo, Dummer Reinhard, Hoek Keith S

Abstract excerpt

Oncogenic mutations within the MAPK pathway are frequent in melanoma, and targeting of MAPK signaling has yielded spectacular responses in a significant number of patients that last for several months before relapsing. We investigated the effects of two different inhibitors of MAPK signaling in proliferative and invasive melanoma cell cultures with various mutations in the MAPK pathway. Proliferative melanoma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enzyme Inhibitors
Share to MAP Kinase Signaling System

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Microarray Analysis

Share to Mitogen-Activated Protein Kinase Kinases

Share to Neoplasm Invasiveness

Share to Proto-Oncogene Proteins B-raf

Share to raf Kinases

Source

Identifiers

PMID: 21176117
DOI: 10.1111/j.1755-148X.2010.00823.x

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status.PMID 21176117Read ↗

The role of mitogen-activated protein targeting in melanoma beyond BRAFV600.Semantic proximity Read ↗

The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition.Semantic proximity Read ↗

RAF-Mutant Melanomas Differentially Depend on ERK2 Over ERK1 to Support Aberrant MAPK Pathway Activation and Cell Proliferation.Semantic proximity Read ↗

Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma.Semantic proximity Read ↗

MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint InhibitorsSemantic proximity Read ↗

Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.Semantic proximity Read ↗

Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma.Semantic proximity Read ↗

<i>In vivo</i> Switching of Human Melanoma Cells between Proliferative and Invasive StatesSemantic proximity Read ↗

A critical role of FAK signaling in Rac1-driven melanoma cell resistance to MAPK pathway inhibitionSemantic proximity Read ↗

Combinatorial Treatment with PARP and MAPK Inhibitors Overcomes Phenotype Switch-Driven Drug Resistance in Advanced Melanoma.Semantic proximity Read ↗

Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma.Semantic proximity Read ↗

Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.